1. Home
  2. RNXT vs GRCE Comparison

RNXT vs GRCE Comparison

Compare RNXT & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNXT
  • GRCE
  • Stock Information
  • Founded
  • RNXT 2012
  • GRCE 2002
  • Country
  • RNXT United States
  • GRCE United States
  • Employees
  • RNXT N/A
  • GRCE N/A
  • Industry
  • RNXT Biotechnology: Pharmaceutical Preparations
  • GRCE
  • Sector
  • RNXT Health Care
  • GRCE
  • Exchange
  • RNXT Nasdaq
  • GRCE NYSE
  • Market Cap
  • RNXT 31.6M
  • GRCE 35.6M
  • IPO Year
  • RNXT 2021
  • GRCE N/A
  • Fundamental
  • Price
  • RNXT $1.04
  • GRCE $3.45
  • Analyst Decision
  • RNXT Strong Buy
  • GRCE
  • Analyst Count
  • RNXT 1
  • GRCE 0
  • Target Price
  • RNXT $9.00
  • GRCE N/A
  • AVG Volume (30 Days)
  • RNXT 226.9K
  • GRCE 132.1K
  • Earning Date
  • RNXT 03-31-2025
  • GRCE 02-13-2025
  • Dividend Yield
  • RNXT N/A
  • GRCE N/A
  • EPS Growth
  • RNXT N/A
  • GRCE N/A
  • EPS
  • RNXT N/A
  • GRCE N/A
  • Revenue
  • RNXT N/A
  • GRCE N/A
  • Revenue This Year
  • RNXT N/A
  • GRCE N/A
  • Revenue Next Year
  • RNXT N/A
  • GRCE N/A
  • P/E Ratio
  • RNXT N/A
  • GRCE N/A
  • Revenue Growth
  • RNXT N/A
  • GRCE N/A
  • 52 Week Low
  • RNXT $0.77
  • GRCE $2.13
  • 52 Week High
  • RNXT $1.86
  • GRCE $4.97
  • Technical
  • Relative Strength Index (RSI)
  • RNXT 32.70
  • GRCE N/A
  • Support Level
  • RNXT $1.00
  • GRCE N/A
  • Resistance Level
  • RNXT $1.18
  • GRCE N/A
  • Average True Range (ATR)
  • RNXT 0.10
  • GRCE 0.00
  • MACD
  • RNXT -0.04
  • GRCE 0.00
  • Stochastic Oscillator
  • RNXT 8.00
  • GRCE 0.00

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

About GRCE GRACE THERAPEUTICS INC

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.

Share on Social Networks: